C4 Therapeutics (CCCC) EPS (Basic) Growth (1y) (2020 - 2026)
Powered by 
Analysis
C4 Therapeutics (CCCC) EPS (Basic) Growth (1y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | 7.74% |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | -4.72% |
| 3 | Argenx Se | 63.55 Bn | 58.37 Bn | 1.37 Bn | 87.85% |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | 7.59% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.89 Bn | 1.53 Bn | 143.95% |
| 7 | Alnylam Pharmaceuticals | 35.32 Bn | 32.01 Bn | 992.69 Mn | 322.67% |
| 8 | Royalty Pharma | 28.42 Bn | 27.59 Bn | - | -16.29% |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 96.41% |
| 10 | C4 Therapeutics | 495.99 Mn | 242.33 Mn | - | 50.65% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 50.65% |
| Mar 31, 2026 | 46.36% |
| Dec 31, 2025 | 50.70% |
| Sep 30, 2025 | -25.13% |
| Jun 30, 2025 | -42.33% |
| Mar 31, 2025 | 10.34% |
| Dec 31, 2024 | 28.82% |
| Sep 30, 2024 | 35.52% |
| Jun 30, 2024 | 64.83% |
| Mar 31, 2024 | 41.57% |
| Dec 31, 2023 | 8.00% |
| Sep 30, 2023 | 15.90% |
| Jun 30, 2023 | -32.99% |
| Mar 31, 2023 | -9.33% |
| Dec 31, 2022 | -123.78% |
| Sep 30, 2022 | -28.33% |
| Jun 30, 2022 | -6.92% |
| Mar 31, 2022 | -33.30% |
| Dec 31, 2021 | 66.18% |
| Sep 30, 2021 | 97.10% |